Methadone in the Management of Post-Operative Pain in Total Knee Replacement

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age21-75
SponsorAdventHealth

About this trial

The goal of this study is to determine whether one dose of IV methadone given right before surgery will help patients' pain management after a total knee replacement and reduce the amount of pain medications taken in the weeks after surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Provision of signed and dated informed consent from

Stated willingness to comply with all study procedures and availability to attend all required visits for the duration of the study.

Age 21- 75

Unilateral total knee arthroplasty at Colorado Joint Replacement

Disqualifiers

Narcotic use in the past 6 weeks

Current or previous history of drug and alcohol abuse

Tobacco use in the previous 90 days

Treatment with another investigational drug

Trial design

Design model

Parallel

Treatments tested in this trial

  • Methadone

    Drug

    Subjects randomized to receive methadone will be given one dose of methadone 0.15mg/kg intravenously dosed based on ideal body weight administered by the anesthesia team prior to surgical incision

Treatment groups

192 Participants
are divided into 2 treatment groups
Group A: MethadoneExperimental treatment 1 intervention
Group B: No medicationNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Opioid use for 48 hours post-operatively

Opioid use will be calculated using morphine milligram equivalents (MME). Patients will keep a log to track opioid consumption.

Time frame
48 hours after TKA procedure

Secondary outcomes

1

Defense and Veterans Pain Scale

Using the Defense and Veterans Pain Scale, patients will rate their pain ranging from 0 (no pain) to 10 (severe pain)

Time frame
2 weeks after TKA procedure
2

Opioid-Related Symptom Distress Scale (ORSDS)

4-point scale that evaluates 12 symptoms in 3 symptom categories including frequency, severity, and bothersomeness. The ORSDS may be used to calculate a symptom-specific score, which is the average of the 3 symptom distress dimensions and range from 0 to 4. The composite ORSDS score is the mean of all 12 symptom-specific scores. Composite ORSDS scores range from 0 to 4.

Time frame
At baseline and 2 weeks after TKA procedure
3

Pittsburgh Sleep Quality Index

Patients will complete survey to monitor sleeping habits

Time frame
At baseline and 2 weeks after TKA procedure
4

Total opioid usage over 2 weeks post-operatively

Opioid use will be calculated using morphine milligram equivalents (MME). Patients will keep a log to track opioid consumption.

Time frame
2 weeks after TKA procedure

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.